$7.35
8.84%
Downside
Day's Volatility :8.84%
Upside
0.0%
56.87%
Downside
52 Weeks Volatility :58.45%
Upside
3.67%
Period | Mannkind Corp. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 45.45% | 0.1% | 0.0% |
6 Months | 70.42% | 4.8% | 0.0% |
1 Year | 111.67% | 19.6% | 0.0% |
3 Years | 53.02% | 12.8% | -27.1% |
Market Capitalization | 2.0B |
Book Value | -$0.82 |
Earnings Per Share (EPS) | 0.05 |
PE Ratio | 147.8 |
PEG Ratio | -0.23 |
Wall Street Target Price | 7.8 |
Profit Margin | 4.73% |
Operating Margin TTM | 22.22% |
Return On Assets TTM | 7.44% |
Return On Equity TTM | 0.0% |
Revenue TTM | 248.4M |
Revenue Per Share TTM | 0.92 |
Quarterly Revenue Growth YOY | 48.9% |
Gross Profit TTM | 42.3M |
EBITDA | 50.4M |
Diluted Eps TTM | 0.05 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.09 |
EPS Estimate Next Year | 0.17 |
EPS Estimate Current Quarter | 0.01 |
EPS Estimate Next Quarter | 0.03 |
What analysts predicted
Upside of 6.12%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 27.9M | ↑ 137.2% |
Net Income | -87.0M | ↓ 25.87% |
Net Profit Margin | -312.2% | ↑ 686.8% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 63.0M | ↑ 126.28% |
Net Income | -59.7M | ↓ 31.33% |
Net Profit Margin | -94.75% | ↑ 217.45% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 65.1M | ↑ 3.34% |
Net Income | -57.2M | ↓ 4.17% |
Net Profit Margin | -87.87% | ↑ 6.88% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 75.4M | ↑ 15.81% |
Net Income | -91.8M | ↑ 60.36% |
Net Profit Margin | -121.67% | ↓ 33.8% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 99.8M | ↑ 32.25% |
Net Income | -112.2M | ↑ 22.2% |
Net Profit Margin | -112.43% | ↑ 9.24% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 199.0M | ↑ 99.42% |
Net Income | -11.9M | ↓ 89.36% |
Net Profit Margin | -6.0% | ↑ 106.43% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 48.6M | ↑ 19.65% |
Net Income | -5.3M | ↓ 67.13% |
Net Profit Margin | -10.83% | ↑ 28.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 51.3M | ↑ 5.43% |
Net Income | 1.7M | ↓ 132.69% |
Net Profit Margin | 3.36% | ↑ 14.19% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 58.5M | ↑ 14.09% |
Net Income | 1.4M | ↓ 18.59% |
Net Profit Margin | 2.4% | ↓ 0.96% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 66.3M | ↑ 13.32% |
Net Income | 10.6M | ↑ 658.74% |
Net Profit Margin | 16.04% | ↑ 13.64% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 72.4M | ↑ 9.24% |
Net Income | -2.0M | ↓ 118.95% |
Net Profit Margin | -2.78% | ↓ 18.82% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 19.7M | ↓ 72.75% |
Net Income | 11.6M | ↓ 673.49% |
Net Profit Margin | 58.55% | ↑ 61.33% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 107.7M | ↑ 27.35% |
Total Liabilities | 282.8M | ↓ 5.52% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 93.7M | ↓ 12.98% |
Total Liabilities | 284.3M | ↑ 0.52% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 108.6M | ↑ 15.88% |
Total Liabilities | 289.0M | ↑ 1.68% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 321.2M | ↑ 195.71% |
Total Liabilities | 530.5M | ↑ 83.55% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 295.3M | ↓ 8.06% |
Total Liabilities | 545.8M | ↑ 2.89% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 475.2M | ↑ 60.93% |
Total Liabilities | 721.4M | ↑ 32.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 313.4M | ↑ 5.13% |
Total Liabilities | 573.9M | ↑ 3.68% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 320.3M | ↑ 2.2% |
Total Liabilities | 572.1M | ↓ 0.31% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 475.2M | ↑ 48.35% |
Total Liabilities | 721.4M | ↑ 26.09% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 480.9M | ↑ 1.2% |
Total Liabilities | 710.8M | ↓ 1.46% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 443.8M | ↓ 7.7% |
Total Liabilities | 669.6M | ↓ 5.8% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 464.2M | ↑ 4.59% |
Total Liabilities | 674.1M | ↑ 0.67% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.7M | ↓ 41.75% |
Investing Cash Flow | -234.0K | ↓ 101.4% |
Financing Cash Flow | 61.3M | ↓ 16.68% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -88.5M | ↑ 134.51% |
Investing Cash Flow | -22.8M | ↑ 9661.97% |
Financing Cash Flow | 69.9M | ↑ 13.98% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.1M | ↓ 68.21% |
Investing Cash Flow | 15.2M | ↓ 166.61% |
Financing Cash Flow | 49.9M | ↓ 28.64% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -61.7M | ↑ 119.39% |
Investing Cash Flow | -151.5M | ↓ 1095.91% |
Financing Cash Flow | 270.3M | ↑ 442.13% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -80.7M | ↑ 30.74% |
Investing Cash Flow | 4.9M | ↓ 103.22% |
Financing Cash Flow | 21.4M | ↓ 92.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.6M | ↑ 124.57% |
Investing Cash Flow | 3.7M | ↓ 73.43% |
Financing Cash Flow | -5.9M | ↓ 581.4% |
Sell
Neutral
Buy
Mannkind Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Mannkind Corp. | 14.23% | 70.42% | 111.67% | 53.02% | 492.34% |
Regeneron Pharmaceuticals, Inc. | -18.16% | -14.42% | 3.52% | 34.42% | 140.62% |
Biontech Se | -5.81% | 20.18% | 11.4% | -51.12% | 460.49% |
Alnylam Pharmaceuticals, Inc. | 2.41% | 83.28% | 68.63% | 50.84% | 200.09% |
Vertex Pharmaceuticals Incorporated | 10.42% | 23.33% | 40.2% | 170.42% | 155.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Mannkind Corp. | 147.8 | 147.8 | -0.23 | 0.09 | 0.0 | 0.07 | NA | -0.82 |
Regeneron Pharmaceuticals, Inc. | 20.41 | 20.41 | 1.2 | 44.89 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.1 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.13 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Mannkind Corp. | Buy | $2.0B | 492.34% | 147.8 | 4.73% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.6B | 140.62% | 20.41 | 33.61% |
Biontech Se | Buy | $25.9B | 460.49% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.1B | 200.09% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $128.9B | 155.94% | 32.84 | -4.51% |
Insights on Mannkind Corp.
Revenue is down for the last 2 quarters, 72.38M → 19.72M (in $), with an average decrease of 72.8% per quarter
Netprofit is up for the last 2 quarters, -2.01M → 11.55M (in $), with an average increase of 117.4% per quarter
BlackRock Inc
Vanguard Group Inc
Nitorum Capital, L.P.
State Street Corp
venBio Select Advisor LLC
Geode Capital Management, LLC
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
Organization | Mannkind Corp. |
Employees | 411 |
CEO | Dr. Michael E. Castagna Pharm.D. |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$7.35
-0.61%
Rigel Resource Acquisition Corp
$7.35
-0.61%
Fortune Rise Acquisition Corp
$7.35
-0.61%
Canada Goose Holdings Inc.
$7.35
-0.61%
J W Mays Inc
$7.35
-0.61%
American Shared Hospital Services
$7.35
-0.61%
Cambria Shareholder Yield Etf
$7.35
-0.61%
J-long Group Ltd.
$7.35
-0.61%
Cps Technologies Corp
$7.35
-0.61%